BPC-157 vs TB-500
Reviewed by the BestHealingPeptides Editorial Team ·
BPC-157 and TB-500 are the two most-discussed research peptides in soft-tissue repair. They have overlapping interest areas — tendon, ligament, and vascular healing — but operate by different mechanisms and rest on quite different bodies of evidence.
BPC-157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
TB-500
A synthetic peptide commonly described as a fragment of thymosin beta-4 incorporating the actin-binding 'LKKTETQ' motif. Studied for soft-tissue repair, wound healing, and cardiac tissue regeneration in animal models.
| Aspect | BPC-157 | TB-500 |
|---|---|---|
| Lead mechanism | VEGFR2-Akt-eNOS angiogenesis + GH-receptor upregulation in tenocytes | G-actin sequestration → cell migration; VEGF upregulation |
| Plasma half-life | <1 hour (rodent) | Short; data sparse for fragment specifically |
| Routes studied | Subcutaneous, IP, oral, topical (route-independent) | Subcutaneous, IM (research) |
| Evidence depth | 100+ indexed pre-clinical studies, mostly Sikiric group | Smaller; many cite full-length Tβ4 rather than fragment |
| WADA category | S0 (non-approved substances) | S2 (peptide hormones / growth factors / mimetics) |
| MHRA status | Not licensed | Not licensed |
Mechanism
BPC-157 acts primarily on the nitric-oxide system and growth-hormone-receptor expression in tendon fibroblasts, with documented angiogenic effects via VEGFR2-eNOS signalling. TB-500 (a fragment of thymosin beta-4) is described as an actin-binding peptide that mobilises cellular migration and upregulates laminin-5, MMP-2/-9, and VEGF.
Evidence base
BPC-157 has accumulated over 100 indexed pre-clinical studies, largely from the Sikiric group. TB-500's published literature is smaller; many citations refer to full-length Tβ4 rather than the commercial fragment, an important caveat when interpreting outcomes.
Half-life and route
BPC-157 has a short plasma half-life (<1 hour in rodents) with rapid distribution; commercial TB-500 is generally administered by subcutaneous or intramuscular injection in research protocols.
Anti-doping
Both peptides are prohibited by WADA — BPC-157 under S0 (non-approved substances), TB-500 under S2 (peptide hormones, growth factors, related substances and mimetics).
Stacking considerations
Anecdotal research-community use frequently combines the two on the basis that BPC-157 contributes vascular/anti-inflammatory effects while TB-500 contributes cell-migration effects. Formal pharmacological evidence for additive or synergistic action in controlled studies is limited.
Verdict
For tendon and ligament research, BPC-157 currently has the deeper published evidence base; TB-500 remains of interest particularly for migration-dependent processes such as cardiac and corneal repair, but batch identity and fragment-vs-full-length distinctions matter.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.